quinta-feira, 12 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

26 Top Dividend Stocks to Buy and Hold in 2026

View original at finance.yahoo.com
26 Top Dividend Stocks to Buy and Hold in 2026 Key Points Top dividend stocks for 2026 include many that offer ultra-high yields of over 6%…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Top dividend stocks for 2026 include many that offer ultra-high yields of over 6%

    80% confidence

  • Alphabet checks off nearly every box in the AI arena, with a top-three cloud platform, a leading large language model (LLM), and AI chips that are gaining market momentum

    80% confidence

  • UnitedHealth Group's stock could bounce back in 2026 after struggling in 2025

    80% confidence

  • Stock Advisor's total average return is 966% compared to 194% for the S&P 500

    80% confidence

  • Identified 10 best stocks for investors to buy now, and Alphabet wasn't one of them

    80% confidence

  • Enbridge is the most intriguing stock in the energy group

    80% confidence

  • AbbVie has roared back after facing patent cliff with Humira and is one of the best healthcare stocks on the market for income investors

    80% confidence

Data points we hold from this source

AbbVie Inc. · market cap405 billion_USD
The Coca-Cola Company · market cap301 billion_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
26 Top Dividend Stocks to Buy and Hold in 2026 — Source | Via News | pt.VIA.NEWS